Beata Korytowsky

PS01.73: Have We Shifted the Therapeutic Innovation Frontier? A US Assessment of Advanced Non–Small Cell Lung Cancer (advNSCLC): Topic: Medical Oncology

to estimate the future burden of cancer care costs through 2040. Methods: Data were taken from Truven MarketScan® claims for patients aged 18+ diagnosed with lung cancer 7/1/2007-8/1/2014 and treated with chemotherapy or biologic/targeted therapy without prior cancer/treatment or concurrent diagnosis of small cell lung cancer. Costs were adjusted for inflation and reported in 2014 USD using the medical care component of the Consumer Price Index (CPI). Autoregressive error models were explored to fit the cost data. Best models were determined based on the goodness-of-fit statistics. Projected future costs with 95% confidence intervals (CIs) were reported based on the extrapolation of the best models. Results: Claims data from 42,953 eligible patients with NSCLC were included in this study (54.4% male; median age, 64 years). Median total cost of care (allcause costs) during first(1L) and second-line (2L) therapy was

ORAL01.02: Biopsies in Initial Diagnosis of Non–Small Cell Lung Cancer in US Community Oncology Practices: Implications for First-Line Immunotherapy: Topic: Medical Oncology

349.90 and

PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC: Topic: Medical Oncology

81.90 for patients and

PS01.74: Systemic Treatment Sequencing in US Medicare Patients with Extensive Disease (ED)-Small Cell Lung Cancer (SCLC): Topic: Medical Oncology.

25,602.50 and

P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153: Topic: IT

11,492.70 for insurers, respectively. For 1L therapy by payer type, mean/median all-cause costs were

The Novel Generation And Validation of Survival Curves In Oncology Utilizing Electronic Medical Records Linked To Point of Service Claims Data

806.70/

Cost of Care in Advanced Non-Small Cell Lung Cancer (ANSCLC) in the Immuno-Oncology (IO) ERA: A Real-World Analysis of Early Data

345.70 (commercial) and

Validation of a Claims-Based Algorithm for Identification of Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the US

1214.40/

Impact of Human Papillomavirus (HPV) Etiology and Immuno-Oncology Therapy (IO) Availability on the Patient Journey In Squamous Cell Carcinoma of the Head and Neck (SCCHN)

313.60 (Medicare), respectively. Overall, mean treatment-related patient and insurer costs are projected to reach

P3.01-57 Real-World (RW) Predictors of Immuno-Oncology (IO) vs Chemotherapy (C) Use in Advanced Non-Small Cell Lung Cancer (aNSCLC)

1,617.69 and